CN113728232A - 作为癌症中的生物标志物的il-4r - Google Patents

作为癌症中的生物标志物的il-4r Download PDF

Info

Publication number
CN113728232A
CN113728232A CN202080024878.2A CN202080024878A CN113728232A CN 113728232 A CN113728232 A CN 113728232A CN 202080024878 A CN202080024878 A CN 202080024878A CN 113728232 A CN113728232 A CN 113728232A
Authority
CN
China
Prior art keywords
cancer
targeting
cells
cargo
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080024878.2A
Other languages
English (en)
Chinese (zh)
Inventor
法赫尔·麦钱特
罗斯米娜·麦钱特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicenna Therapeutics Pte Ltd
Original Assignee
Medicenna Therapeutics Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicenna Therapeutics Pte Ltd filed Critical Medicenna Therapeutics Pte Ltd
Publication of CN113728232A publication Critical patent/CN113728232A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN202080024878.2A 2019-02-07 2020-02-07 作为癌症中的生物标志物的il-4r Pending CN113728232A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962802652P 2019-02-07 2019-02-07
US62/802,652 2019-02-07
PCT/CA2020/000013 WO2020160639A1 (en) 2019-02-07 2020-02-07 Il-4r as a biomarker in cancer

Publications (1)

Publication Number Publication Date
CN113728232A true CN113728232A (zh) 2021-11-30

Family

ID=71946943

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080024878.2A Pending CN113728232A (zh) 2019-02-07 2020-02-07 作为癌症中的生物标志物的il-4r

Country Status (6)

Country Link
US (1) US20220347268A1 (https=)
EP (1) EP3921637A1 (https=)
JP (1) JP2022519377A (https=)
CN (1) CN113728232A (https=)
CA (1) CA3129200A1 (https=)
WO (1) WO2020160639A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104619334A (zh) 2012-08-09 2015-05-13 利兰斯坦福初级大学董事会 超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子
EP3049526B1 (en) 2013-09-24 2021-02-24 Medicenna Therapeutics, Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof
CN111201035A (zh) 2017-06-19 2020-05-26 梅迪塞纳医疗股份有限公司 Il-2超激动剂、激动剂及其融合体的用途和方法
EP3694558B1 (en) 2017-10-10 2024-04-10 Medicenna Therapeutics Inc. Il-4-fusion formulations for treatment of central nervous system (cns) tumors
US12590133B2 (en) 2018-06-01 2026-03-31 The Board Of Trustees Of The Leland Stanford Junior University IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof
WO2019239213A2 (en) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
EP4225377A4 (en) * 2020-10-12 2024-11-27 Medicenna Therapeutics, Inc. COMBINATION THERAPY WITH MDNS55 AND A VASCULAR ENDOTHELIAL GROWTH FACTOR A (VEGF-A)
CN118146395A (zh) * 2021-02-08 2024-06-07 浙江大学 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
US20240239857A1 (en) * 2021-05-19 2024-07-18 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Il-13ralpha2 targeted immunotoxins and methods of use
WO2023102193A1 (en) * 2021-12-02 2023-06-08 Ohio State Innovation Foundation Methods and compositions related to inflammatory gene panel
WO2024214083A1 (en) * 2023-04-14 2024-10-17 Medicenna Therapeutics Inc. Use of immunomodulation methods in combination with cytokine fusions for disease treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120294931A1 (en) * 2009-12-29 2012-11-22 Kyungpook National University Industry-Academic Cooperation Foundation Target-aiming drug delivery system for diagnosis and treatment of cancer containing liposome labeled with peptides which specifically targets interleukin-4 receptors, and manufacturing method thereof
US20160271231A1 (en) * 2008-09-19 2016-09-22 Medicenna Therapeutics Inc. Treating cancer stem cells using targeted cargo proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10849960B2 (en) * 2017-09-08 2020-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer
EP3694558B1 (en) * 2017-10-10 2024-04-10 Medicenna Therapeutics Inc. Il-4-fusion formulations for treatment of central nervous system (cns) tumors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160271231A1 (en) * 2008-09-19 2016-09-22 Medicenna Therapeutics Inc. Treating cancer stem cells using targeted cargo proteins
US20120294931A1 (en) * 2009-12-29 2012-11-22 Kyungpook National University Industry-Academic Cooperation Foundation Target-aiming drug delivery system for diagnosis and treatment of cancer containing liposome labeled with peptides which specifically targets interleukin-4 receptors, and manufacturing method thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRYAN M. BURT等: ""Expression of Interleukin-4 Receptor Alpha in Human Pleural Mesothelioma Is Associated with Poor Survival and Promotion of Tumor Inflammation"", 《CLINICAL CANCER RESEARCH》, vol. 18, no. 6, 15 March 2012 (2012-03-15), pages 1569 - 1570 *
JING HAN等: "Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme", 《JOURNAL OF NEURO-ONCOLOGY》, vol. 136, no. 3, 22 November 2017 (2017-11-22), pages 463 - 474, XP036421378, DOI: 10.1007/s11060-017-2680-9 *
LINDA GARLAND等: "（"Phase I Trial of Intravenous IL-4 Pseudomonas Exotoxin Protein (NBI-3001) in Patients with Advanced Solid Tumors That Express the IL-4 Receptor"", 《JOURNAL OF IMMUNOTHERAPY》, vol. 28, no. 4, 30 December 2005 (2005-12-30), pages 378 - 381, XP008146351 *

Also Published As

Publication number Publication date
WO2020160639A1 (en) 2020-08-13
US20220347268A1 (en) 2022-11-03
CA3129200A1 (en) 2020-08-13
EP3921637A1 (en) 2021-12-15
JP2022519377A (ja) 2022-03-23

Similar Documents

Publication Publication Date Title
CN113728232A (zh) 作为癌症中的生物标志物的il-4r
US12338269B2 (en) IL-2 superagonists in combination with anti-PD-1 antibodies
JP7843702B2 (ja) 細胞外小胞をプログラムするための組換えポリペプチド
CN110730908B (zh) 表达前列腺特异性膜抗原（psma）或其修饰形式的工程化细胞及相关方法
US11692034B2 (en) CD47-CAR-T cells
US20230365642A1 (en) Bifunctional superkines and uses thereof
US12404497B2 (en) Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof
Molloy et al. Preclinical characterization of HPN536, a trispecific, T-cell–activating protein construct for the treatment of mesothelin-expressing solid tumors
ES2433967T3 (es) Productos de fusión anticuerpo-LIGHT como productos terapéuticos de cáncer
BR112020003842A2 (pt) adenovírus armado com aglutinante biespecífico de células t (bite)
CN107523545A (zh) 一种高效稳定表达抗体的杀伤性细胞及其用途
CN107523547A (zh) 一种高效稳定表达抑制性抗体的car‑t细胞及其用途
KR20210094535A (ko) 4-1bbl (cd137l) 및/또는 cd40l를 암호화하는 재조합 mva의 종양내 및/또는 정맥내 투여에 의한 암의 치료 방법
Wang et al. PiggyBac-engineered T cells expressing a glypican-3-specific chimeric antigen receptor show potent activities against hepatocellular carcinoma
CN112533943A (zh) Il-13/il-4超级因子：免疫细胞靶向性构建体及其使用方法
US20230190922A1 (en) Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer
Li et al. An oncolytic vaccinia virus expressing anti-CD47 nanobody exerts enhanced antitumor activity by mediating innate and adaptive immune cell infiltration and activation in the lymphoma tumor microenvironment
US20220177599A1 (en) Dual chimeric antigen receptor targeting epcam and icam-1
US20240156868A1 (en) Recombinant tim-4 protein, chimeric antigen receptor (car) t cell delivery system and methods of making and using same
Tang et al. Strengthening of antitumor effects in breast cancer from a novel B7-H4-and CD3-targeting bispecific antibody by an oncolytic virus
KR20220070440A (ko) 치료학적 항체와 인터루킨-2 (il2)를 수반한 치료
WO2025189420A1 (en) Chimeric antigen receptor against programmed deathligand 1 (pd-l1) and application thereof
US20250288674A1 (en) Chimeric antigen receptor against programmed death ligand 1 (pd-l1) and application thereof
US20250313648A1 (en) Binders of Chondroitin Sulfate Proteoglycan (CSPG4) Polypeptides
KR20260057409A (ko) Il-2 융합 단백질

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211130